Seshadri S, Beiser A, Selhub J, et al
Two large 72-week clinical trials that evaluated terzepatide in individuals who were overweight or obese found that by the end of the study, people who also dieted and exercised reported statistically significant weight loss compared to those who took the placebo

Get the Injury, Joint & Recovery Blueprint *Educational only No protocols Written by clinicians* When to Use BPC-157 + TB-500 This blend is ideal for a range of patients and scenarios, including: Athletes looking to recover from training faster Post-surgical patients needing accelerated healing Individuals with tendinopathy , ligament sprains , or joint instability Chronic pain sufferers seeking regenerative alternatives Patients with gut inflammation or leaky gut (BPC-157 has GI-healing properties) People with connective tissue disorders or injury-prone joints Individuals experiencing inflammatory joint conditions (such as arthritis) Expected Results While every patient responds differently, many experience: Reduced pain and inflammation within 12 weeks Enhanced range of motion and tissue resilience Accelerated recovery time from injuries or surgeries Improved mobility and flexibility Reduced gut permeability and inflammation (via BPC-157) Peak results are typically seen 48 weeks into therapy, depending on severity and dosing

nobelprize.org
Why "fat burner" framing doesn't hold up An accurate fat-loss tool typically influences at least one of these directly: Appetite and satiety regulation Energy expenditure/thermogenesis Lipolysis and fat oxidation pathways Glucose regulation in a clinically meaningful way BPC-157 has not been established as reliably effective in humans for those categories of fat loss
Its dual route of administration, oral and intravenous, provides dosing flexibility, which is particularly beneficial for long-term outpatient management